New York State Teachers Retirement System Has $1.57 Million Stock Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

New York State Teachers Retirement System trimmed its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 3.0% during the fourth quarter, HoldingsChannel reports. The firm owned 60,476 shares of the medical equipment provider’s stock after selling 1,900 shares during the quarter. New York State Teachers Retirement System’s holdings in BioLife Solutions were worth $1,570,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp lifted its position in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after purchasing an additional 18,473 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after purchasing an additional 262,504 shares during the last quarter. Stephens Investment Management Group LLC grew its stake in BioLife Solutions by 16.7% in the 4th quarter. Stephens Investment Management Group LLC now owns 495,970 shares of the medical equipment provider’s stock valued at $12,875,000 after buying an additional 70,875 shares during the last quarter. Finally, Curi RMB Capital LLC grew its stake in BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after buying an additional 2,283 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Insider Buying and Selling at BioLife Solutions

In other news, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,678 shares of company stock worth $317,990 over the last three months. 2.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BLFS has been the topic of a number of research reports. TD Cowen upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum upped their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Northland Securities increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Stock Down 3.1 %

BioLife Solutions stock opened at $26.67 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $29.55. The stock has a market cap of $1.24 billion, a PE ratio of -25.16 and a beta of 1.91. The firm’s 50-day simple moving average is $26.93 and its 200 day simple moving average is $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.